<p>IDEXX Laboratories Inc. reported fourth quarter (Q4) 2025 revenues of USD 1.09 billion, reflecting a 14% increase compared to the prior year period. The Companion Animal Group (CAG) segment achieved reported revenue growth of 15%, while Water revenue grew 12% year-over-year. Earnings per diluted share (EPS) for Q4 2025 were USD 3.08, up 18%, with operating margin expansion of 1.5 percentage points. For the full year (FY) 2025, IDEXX Laboratories highlighted continued strong execution, driven by the successful launch of the IDEXX Cancer Dx canine lymphoma test and significant adoption of the IDEXX inVue Dx instrument, both of which exceeded initial adoption targets. The company also noted positive impacts from currency changes and tax benefits related to share-based compensation during the quarter. IDEXX Laboratories Inc. enters 2026 with an expanded innovation pipeline and plans to build on its installed base of premium instruments and further international expansion of its diagnostics solutions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEXX Laboratories Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260130438354) on February 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

IDEXX reports Q4 2025 revenue of USD 1.09 billion, up 14%